213 related articles for article (PubMed ID: 37022702)
1. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.
Tang C; Sherry AD; Haymaker C; Bathala T; Liu S; Fellman B; Cohen L; Aparicio A; Zurita AJ; Reuben A; Marmonti E; Chun SG; Reddy JP; Ghia A; McGuire S; Efstathiou E; Wang J; Wang J; Pilie P; Kovitz C; Du W; Simiele SJ; Kumar R; Borghero Y; Shi Z; Chapin B; Gomez D; Wistuba I; Corn PG
JAMA Oncol; 2023 Jun; 9(6):825-834. PubMed ID: 37022702
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Phillips R; Shi WY; Deek M; Radwan N; Lim SJ; Antonarakis ES; Rowe SP; Ross AE; Gorin MA; Deville C; Greco SC; Wang H; Denmeade SR; Paller CJ; Dipasquale S; DeWeese TL; Song DY; Wang H; Carducci MA; Pienta KJ; Pomper MG; Dicker AP; Eisenberger MA; Alizadeh AA; Diehn M; Tran PT
JAMA Oncol; 2020 May; 6(5):650-659. PubMed ID: 32215577
[TBL] [Abstract][Full Text] [Related]
3. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
Privé BM; Janssen MJR; van Oort IM; Muselaers CHJ; Jonker MA; de Groot M; Mehra N; Verzijlbergen JF; Scheenen TWJ; Zámecnik P; Barentsz JO; Gotthardt M; Noordzij W; Vogel WV; Bergman AM; van der Poel HG; Vis AN; Oprea-Lager DE; Gerritsen WR; Witjes JA; Nagarajah J
BMC Cancer; 2020 Sep; 20(1):884. PubMed ID: 32928177
[TBL] [Abstract][Full Text] [Related]
4. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
[TBL] [Abstract][Full Text] [Related]
5. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
7. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
Oudard S; Latorzeff I; Caty A; Miglianico L; Sevin E; Hardy-Bessard AC; Delva R; Rolland F; Mouret L; Priou F; Beuzeboc P; Gravis G; Linassier C; Gomez P; Voog E; Muracciole X; Abraham C; Banu E; Ferrero JM; Ravaud A; Krakowski I; Lagrange JL; Deplanque G; Zylberait D; Bozec L; Houede N; Culine S; Elaidi R
JAMA Oncol; 2019 May; 5(5):623-632. PubMed ID: 30703190
[TBL] [Abstract][Full Text] [Related]
8. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
9. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
Wenzel M; Garcia CC; Hoeh B; Jorias C; Humke C; Koll F; Tselis N; Rödel C; Graefen M; Tilki D; Chun FKH; Mandel P
Prostate; 2023 Oct; 83(14):1365-1372. PubMed ID: 37464963
[TBL] [Abstract][Full Text] [Related]
10. Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.
Glicksman RM; Ramotar M; Metser U; Chung PW; Liu Z; Vines D; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):693-704. PubMed ID: 36031465
[TBL] [Abstract][Full Text] [Related]
11. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
Parikh NR; Huiza C; Patel JS; Tsai S; Kalpage N; Thein M; Pitcher S; Lee SP; Inouye WS; Jordan ML; Sanati H; Jafari L; Bennett CJ; Gin GE; Kishan AU; Reiter RE; Lewis M; Sadeghi A; Aronson WJ; Garraway IP; Rettig MB; Nickols NG
BMC Cancer; 2019 Apr; 19(1):291. PubMed ID: 30935383
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
13. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
Rans K; Charlien B; Filip A; Olivier H; Julie DH; Céderic D; Herlinde D; Benedikt E; Karolien G; Annouschka L; Nick L; Kenneth P; Carl S; Koen S; Hans V; Ben V; Steven J; Gert M
BMC Cancer; 2022 Dec; 22(1):1294. PubMed ID: 36503429
[TBL] [Abstract][Full Text] [Related]
14. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND.
Sherry AD; Bathala TK; Liu S; Fellman BM; Chun SG; Jasani N; Guadagnolo BA; Jhingran A; Reddy JP; Corn PG; Shah AY; Kaiser KW; Ghia AJ; Gomez DR; Tang C
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):910-918. PubMed ID: 35691448
[TBL] [Abstract][Full Text] [Related]
15. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
Spaas M; Sundahl N; Kruse V; Rottey S; De Maeseneer D; Duprez F; Lievens Y; Surmont V; Brochez L; Reynders D; Danckaert W; Goetghebeur E; Van den Begin R; Van Gestel D; Renard V; Dirix P; Ost P
JAMA Oncol; 2023 Sep; 9(9):1205-1213. PubMed ID: 37410476
[TBL] [Abstract][Full Text] [Related]
20. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial.
Ng K; Nimeiri HS; McCleary NJ; Abrams TA; Yurgelun MB; Cleary JM; Rubinson DA; Schrag D; Miksad R; Bullock AJ; Allen J; Zuckerman D; Chan E; Chan JA; Wolpin BM; Constantine M; Weckstein DJ; Faggen MA; Thomas CA; Kournioti C; Yuan C; Ganser C; Wilkinson B; Mackintosh C; Zheng H; Hollis BW; Meyerhardt JA; Fuchs CS
JAMA; 2019 Apr; 321(14):1370-1379. PubMed ID: 30964527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
